These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29398980)

  • 1. Reconstructing time-to-event data from published Kaplan-Meier curves.
    Wei Y; Royston P
    Stata J; 2017 Oct; 17(4):786-802. PubMed ID: 29398980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
    Guyot P; Ades AE; Ouwens MJ; Welton NJ
    BMC Med Res Methodol; 2012 Feb; 12():9. PubMed ID: 22297116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical guide to understanding Kaplan-Meier curves.
    Rich JT; Neely JG; Paniello RC; Voelker CC; Nussenbaum B; Wang EW
    Otolaryngol Head Neck Surg; 2010 Sep; 143(3):331-6. PubMed ID: 20723767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.
    Liu N; Zhou Y; Lee JJ
    BMC Med Res Methodol; 2021 Jun; 21(1):111. PubMed ID: 34074267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve.
    Messori A
    Cureus; 2021 Nov; 13(11):e19422. PubMed ID: 34786276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Method for Reconstructing Individual Patient Data From Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times.
    Rogula B; Lozano-Ortega G; Johnston KM
    MDM Policy Pract; 2022; 7(1):23814683221077643. PubMed ID: 35128059
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.
    Saluja R; Cheng S; Delos Santos KA; Chan KKW
    Res Synth Methods; 2019 Sep; 10(3):465-475. PubMed ID: 31134735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cautionary Note on Extended Kaplan-Meier Curves for Time-varying Covariates.
    Sjölander A
    Epidemiology; 2020 Jul; 31(4):517-522. PubMed ID: 32282405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer.
    Coory M; Lamb KE; Sorich M
    J Clin Epidemiol; 2014 Sep; 67(9):966-72. PubMed ID: 24794698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis.
    Hirooka T; Hamada C; Yoshimura I
    Methods Inf Med; 2009; 48(2):104-12. PubMed ID: 19283306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.
    Lacny S; Wilson T; Clement F; Roberts DJ; Faris PD; Ghali WA; Marshall DA
    Clin Orthop Relat Res; 2015 Nov; 473(11):3431-42. PubMed ID: 25804881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Utility of Multistate Models: A Flexible Framework for Time-to-Event Data.
    Le-Rademacher JG; Therneau TM; Ou FS
    Curr Epidemiol Rep; 2022; 9(3):183-189. PubMed ID: 36003089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Kaplan-Meier analysis in urological practice].
    Rink M; Kluth LA; Shariat SF; Fisch M; Dahlem R; Dahm P
    Urologe A; 2013 Jun; 52(6):838-41. PubMed ID: 23703691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deconstructing the Kaplan-Meier curve: Quantification of treatment effect using the treatment effect process.
    Devlin SM; O'Quigley J
    Contemp Clin Trials; 2023 Feb; 125():107043. PubMed ID: 36473681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
    Luo H; Zhang C; Wang J; Zhu J; Jia X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An original approach was used to better evaluate the capacity of a prognostic marker using published survival curves.
    Dantan E; Combescure C; Lorent M; Ashton-Chess J; Daguin P; Classe JM; Giral M; Foucher Y
    J Clin Epidemiol; 2014 Apr; 67(4):441-8. PubMed ID: 24581297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention.
    Mengozzi A; Tricò D; Natali A
    Trials; 2020 Jun; 21(1):578. PubMed ID: 32586346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.